Null mutations at the p66 and bradykinin 2 receptor loci induce divergent phenotypes in the diabetic kidney

Himanshu Vashistha, Pravin C. Singhal, Ashwani Malhotra, Mohammad Husain, Peter Mathieson, Moin A. Saleem, Cyril Kuriakose, Surya Seshan, Anna Wilk, Luis DelValle, Francesca Peruzzi, Marco Giorgio, Pier Giuseppe Pelicci, Oliver Smithies, Hyung Suk Kim, Masao Kakoki, Krzysztof Reiss, Leonard G. Meggs

Research output: Contribution to journalArticle

Abstract

Candidate genes have been identified that confer increased risk for diabetic glomerulosclerosis (DG). Mice heterozygous for the Akita (Ins2+/C96Y) diabetogenic mutation with a second mutation introduced at the bradykinin 2 receptor (B2R-/-) locus express a disease phenotype that approximates human DG. Src homology 2 domain transforming protein 1 (p66) controls mitochondrial metabolism and cellular responses to oxidative stress, aging, and apoptosis. We generated p66-null Akita mice to test whether inactivating mutations at the p66 locus will rescue kidneys of Akita mice from disease-causing mutations at the Ins2 and B2R loci. Here we show null mutations at the p66 and B2R loci interact with the Akita (Ins2+/C96Y) mutation, independently and in combination, inducing divergent phenotypes in the kidney. The B2R-/- mutation induces detrimental phenotypes, as judged by increased systemic and renal levels of oxidative stress, histology, and urine albumin excretion, whereas the p66-null mutation confers a powerful protection phenotype. To elucidate the mechanism(s) of the protection phenotype, we turned to our in vitro system. Experiments with cultured podocytes revealed previously unrecognized cross talk between p66 and the redox-sensitive transcription factor p53 that controls hyperglycemia-induced ROS metabolism, transcription of p53 target genes (angiotensinogen, angiotensin II type-1 receptor, and bax), angiotensin II generation, and apoptosis. RNA-interference targeting p66 inhibits all of the above. Finally, protein levels of p53 target genes were upregulated in kidneys of Akita mice but unchanged in p66-null Akita mice. Taken together, p66 is a potential molecular target for therapeutic intervention in DG.

Original languageEnglish
JournalAmerican Journal of Physiology - Renal Physiology
Volume303
Issue number12
DOIs
Publication statusPublished - Dec 15 2012

Keywords

  • Akita mouse
  • Angiotensin II
  • Apoptosis
  • Diabetic glomerulosclerosis
  • Proteinuria

ASJC Scopus subject areas

  • Physiology
  • Urology

Fingerprint Dive into the research topics of 'Null mutations at the p66 and bradykinin 2 receptor loci induce divergent phenotypes in the diabetic kidney'. Together they form a unique fingerprint.

  • Cite this

    Vashistha, H., Singhal, P. C., Malhotra, A., Husain, M., Mathieson, P., Saleem, M. A., Kuriakose, C., Seshan, S., Wilk, A., DelValle, L., Peruzzi, F., Giorgio, M., Pelicci, P. G., Smithies, O., Kim, H. S., Kakoki, M., Reiss, K., & Meggs, L. G. (2012). Null mutations at the p66 and bradykinin 2 receptor loci induce divergent phenotypes in the diabetic kidney. American Journal of Physiology - Renal Physiology, 303(12). https://doi.org/10.1152/ajprenal.00246.2012